Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
GSK's $4.2B bet on Merck KGaA's cancer drug goes up in smoke as pharmas cut ties.
GSK and Merck KGaA break up their $4 billion oncology collaboration after multiple clinical trial failures of bintrafusp alfa, ending a partnership that had…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
GSK and Merck KGaA formed a global immuno-oncology alliance to co-develop and co-commercialize bintrafusp alfa (M7824), a bifunctional TGF-beta trap/anti-PD-L1 fusion protein. GSK paid EUR 300M upfront with up to EUR 500M in development milestones and EUR 2.9B in approval/commercial milestones. The collaboration was terminated September 2021 after multiple clinical trial failures.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Merck KGaA (this deal) | 2019 | $4.2B | 29 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2019 deals · GSK plc deals · Oncology deals